Bryan C. Diner

Bryan’s litigation practice involves diverse technical areas, ranging from protecting the rights of innovative pharmaceutical companies in Abbreviated New Drug Application (ANDA) litigations to defending clients’ right to use certain medical devices. He also has extensive experience in conducting IP due diligence investigations for all types of transactions.

Bryan served as managing partner of the firm’s Brussels office for six years. During his tenure, he learned much about the European legal system, from the European Patent Convention (EPC) to the diversity of laws and practice among the European national systems. Strategic portfolio management and litigation counseling for European clients is also an important part of Bryan’s practice. His knowledge of the European legal system and how it differs from that in the United States allows Bryan to counsel both European and domestic clients on a full range of IP issues and to find cohesive solutions tailored to the needs of companies with global interests.

Bryan lectures at various international programs and conferences targeted to U.S. and European business communities. He is fluent in French and has provided lectures in French on U.S. patent law topics involving litigation and due diligence reviews. He coauthored with other Finnegan lawyers a published course book on due diligence investigations and chemical patent law.

Bryan is recognized as a Life Sciences star by LMG Life Sciences in the fields of “Patent Strategy & Management” and “Hatch-Waxman Patent Litigation,” and was selected as a “U.S. Intellectual Property Life Sciences Rising Star” at the fifth annual LMG Life Sciences awards dinner. The awards honor law firms and attorneys who have made a significant impact in the life sciences industry.

Intellectual Asset Management (IAM) and The Legal 500 U.S. have each recognized Bryan in the areas of patent litigation and prosecution. Managing Intellectual Property (MIP) also named Bryan a notable practitioner on the national and regional (District of Columbia) levels.

NOTE: No aspect of these rankings has been approved by the Supreme Court of New Jersey. Further information on methodologies is available via these links.